Fiverr【F2VR34】銘柄情報 | ADVFN

US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
ブラジル
BOV
Fiverr International Ltd (F2VR34) 銘柄情報

Fiverr International Ltd (F2VR34)

6.61

0.00

(0.00%)

終了 10月12日 5:55AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

6.61

買値

0.00

売値

0.00

出来高

-

0.00 日の範囲 0.00

4.64 52 週間の範囲 7.50

時価総額

前日終値

6.61

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

366

発行済株式数

38,654,000

配当利回り

-

PER

248.11

1 株当たり利益 (EPS)

0.1

歳入

361.38M

純利益

3.68M

セクター

Business Services, Nec

業界

Business Services, Nec

ウェブサイト

www.fiverr.com

本社

Tel Aviv, Center, Isr

設立

-

Fiverr International Ltd is listed in the Business Services sector of the ボベスパ (ブラジル) with ticker F2VR34. The last closing price for Fiverr was R$6.61. Over the last year, Fiverr shares have traded in a share price range of R$ 4.64 to R$ 7.50.

Fiverr currently has 38,654,000 shares in issue. The market capitalisation of Fiverr is R$255.50 million. Fiverr has a price to earnings ratio (PE ratio) of 248.11.

No news to show yet.

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.01	0.151515151515	6.6	6.69	6.43	14	6.46436364	DR
4	-0.21	-3.07917888563	6.82	7.12	6.43	314	6.87975986	DR
12	0.24	3.76766091052	6.37	7.5	6.17	366	7.18356947	DR
26	1.87	39.4514767932	4.74	7.5	4.64	394	6.50141817	DR
52	0.13	2.00617283951	6.48	7.5	4.64	493	6.13345719	DR
156	-43.23	-86.7375601926	49.84	55.09	4.64	2669	9.84774019	DR
260	-37.33	-84.9567592171	43.94	55.29	4.64	2560	9.88392311	DR

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
RCSL4Recrusul Sa	R$ 1.22 (12.96%)	3.06M
TRAD3TC S.A.	R$ 6.42 (9.00%)	409.8k
TPIS3Tpi Triunfo Participacoes Invests Sa	R$ 6.05 (7.65%)	195.9k
AMBP3Ambipar Participacoes e Empreendimentos SA	R$ 133.99 (7.19%)	596.9k
CEAB3C & A Modas S.A.	R$ 11.03 (7.19%)	6.48M
CSAN3QCosan SA	R$ 12.11 (-24.31%)	240.4k
DASA11Diagnosticos da America SA	R$ 0.66 (-17.50%)	1,000
ESTR4Manufatura Brinquedos Estrela Sa	R$ 3.40 (-12.82%)	400
SBSP3QCompanhia de Saneamento Basico do Estado de Sao Paulo.	R$ 87.00 (-10.54%)	1.45M
KRSA3Kora Saude Participacoes S.A	R$ 4.55 (-7.14%)	84.8k
PDGR3PDG Realty S.A. Empreendimentos E Participacoes	R$ 0.01 (0.00%)	104.28M
HAPV3Hapvida Participacoes Investimento SA	R$ 3.88 (1.84%)	54.55M
GGBR4Gerdau Sa	R$ 18.45 (-3.61%)	41.74M
BBDC4Bco Bradesco Sa	R$ 14.80 (-1.33%)	35.34M
AZUL4AZUL SA	R$ 5.93 (2.24%)	33.53M

crescentmotor

crescentmotor 4分前

Anavex a winner with Amazon home delivery of Blarcamesine.

You have a horse way out in front of your carriage. I suggest you rein it in a little in acknowledgement of the current reality; that is, AVXL hasn't even filed an MAA much less had it accepted for review

janice shell

janice shell 8分前

Yeah. Back in the day, DMT was considered to be a dangerously powerful hallucinogen.

No wonder the author says it makes people see fairies. I meant why not?

236T568

236T568 9分前

Well done. A must see

https://x.com/ProjectLincoln/status/1844950873736106424?s=19

sentiment_stocks

sentiment_stocks 12分前

PFS as an endpoint was intended to be used as a surrogate for the OS endpoint, and as it turns out with immunotherapies such as DCVax, it was too difficult to differentiate real PFS from pseudo progression. So the trial instead had to utilize the more important OS endpoint.

But you kn

MinnyTodd

MinnyTodd 13分前

When i did DD on this stock a while ago i found a Ramon Valdez cfo of now defunct Smack Sportswear SMAK in California
Not sure if its the same guy.

Sunman88

Sunman88 23分前

I hear you. It’s stays range bound for now around $9-10, maybe $11-12 later. But it’s not flying anytime within 6 months. Major drivers are NSCLC data and Pembro+Lifileucel for earlier line melanoma. We may get some updates in 6-12 month window which may lift the range to $14-18 if they don’t get

shajandr

shajandr 27分前

Saturday, Billy spent the day in service of UOIP and Chanboned baggholders as he was offshore for 14 hours fishing for licensable patents.

https://investorshub.advfn.com/uimage/uploads/2024/10/12/qquoqUOIP_Billy_deep_sea_fishing_mauritius.jpg

Nott having caught any (pat

janice shell

janice shell 27分前

What?? I don't think Foley's ever sued IHub, unless I'm misremembering:

https://investorshub.advfn.com/boards/legal_ref.aspx

He went to prison because he was sued by the DOJ. And by the SEC, but that was a civil suit. Now he's up on criminal charges again.

trippininLaCoste

trippininLaCoste 27分前

There must have been something special about lot 180. There is nothing special about this fraud.

Do they still have their corporate offices ?

PENNIEStoSTACKS

PENNIEStoSTACKS 29分前

https://baasbox.com/en

https://phonetime.com

doccjc

doccjc 30分前

janice shell

janice shell 31分前

That is creepy AF!!

Genz2

https://finance.yahoo.com/news/microsoft-ceo-satya-nadella-calls-175724818.html

Interesting comment from Yahoo. Maybe just a basher…

Trouble:

I would tell these CEO's to not give him any information or extended access to their information and/or how they

Coo breeze

Coo breeze 45分前

Can you find out the bid and ask ?

SkyLimit2022

SkyLimit2022 46分前

Gro,

https://investorshub.advfn.com/uimage/uploads/2024/9/22/vpafrgiphy.gif

Thanks for reposting that again, but you have reposted that a hundred times. 😶

The PFS data were contaminated by pseudo, so they had to wait for OS data. PFS is a surroga

4u2nv2

4u2nv2 46分前

Most people can answer a question if they own a stock like MCIC or not. Unless they have over 11,500+ reasons to worry about legal issues when answering the question on record.

north40000

north40000 48分前

See www.fiercebiotech.com article dated 2/25/2024.

JNJ closed its 200,000 sq.ft. Brisbane, California R&D facility, laid off 55 workers after hosting a Gene Therapy Summit there on 2/15/2024. Janssen Pharmaceutical is gone, replaced by JNJ Innovative Medicine. JNJ’s $6.5 Phase 3 autoi

againstallodds

againstallodds 48分前

Alford: will you lose your P.Geo license???

HyGro

PFS is certainly NOT a "statistical estimation." In oncology, progression-free survival (PFS) is the time a patient lives with cancer, without it getting worse, from the time of random assignment in a clinical trial until disease progression or death from any cause. PFS is a primary endpoint used

bb8675309

bb8675309 49分前

Anavex a winner with Amazon home delivery of Blarcamesine.

shajandr

shajandr 52分前

"Well, if you do a little research and Google the amount of OTC shells up for sale to potential private companies wanting to go public, it's an over-saturated market. There simply aren't many companies that want to take this route now. Hence, the 100s or 1000s of shells not selling."

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約